Medesis Pharma
  • en
  • fr
  • Corporate
    • General presentation
    • Historical
    • Governance
    • Supervisory board
    • Scientific Advisory board
  • Technology
    • Description
    • Advantages
    • Historical
  • Pipeline
  • Clinical
    • Alzheimer’s disease
  • Pre-clinical
    • Neurology
    • Cancer
    • Nuclear
  • Investors
    • Share information
    • Press release
    • Reports and documents
    • Regulated information
    • General Meetings
    • Agenda & Contact
  • Scientific publications
  • Contacts
Select Page
Medesis Pharma & Transgene prolongent leur accord de recherche collaborative

Medesis Pharma & Transgene prolongent leur accord de recherche collaborative

by Calyptus | Nov 26, 2020 | Press news

MEDESIS PHARMA & TRANSGENE PROLONGENT LEUR ACCORD DE RECHERCHE COLLABORATIVE Montpellier, le 26 novembre 2020 – Medesis Pharma, société de biotechnologie pharmaceutique développant des candidats médicaments avec sa technologie propriétaire d’administration de...
Medesis Pharma propose ses nanoémulsions de NanoManganese® pour traiter le Covid-19

Medesis Pharma propose ses nanoémulsions de NanoManganese® pour traiter le Covid-19

by Gilles Petitot | Mar 27, 2020 | Press news

La technologie de microemulsion de Medesis permet d’encapsuler du manganèse pour le délivrer en intra-cellulaire à très faible dose et déclencher ainsi l’activité de défense des cellules contre l’agression virale et ses graves conséquences inflammatoires  ...
Medesis Pharma and Transgene collaborate to explore the contribution of the Aonys® platform to oncolytic virotherapies

Medesis Pharma and Transgene collaborate to explore the contribution of the Aonys® platform to oncolytic virotherapies

by Gilles Petitot | Jul 12, 2019 | Press news

 July 8, 2019 – MEDESIS PHARMA announces the signing of a collaborative research agreement with TRANSGENE to apply Aonys® technology to the treatment of tumors by oncolytic viruses. This collaboration allows testing of an innovative approach of modulating the...
Alzheimer: What if Medesis Pharma had the right key ?

Alzheimer: What if Medesis Pharma had the right key ?

by Patrick Maurel | Oct 10, 2017 | Press news

AUDIO EDITION : the Montpellier biotech publishes very interesting results with its lipidic microemulsion of Lithium, NP03.   Jean-Claude Maurel,CEO of Medesis Pharma. A preclinical study published by the team of Professor Claudio Cuello, MgGill University Montreal...
Treatment of contaminated populations after a nuclear accident

Treatment of contaminated populations after a nuclear accident

by Gilles Petitot | Sep 28, 2017 | Press news

Treatment of contaminated populations after a nuclear accident: Novel drugs designed by Medesis Pharma proved to be effective Recently published, a scientific article confirms the mode of action of nanoparticles designed by Medesis Pharma. The nanoparticles were made...
“A treatment for Alzheimer’s disease? “

“A treatment for Alzheimer’s disease? “

by Gilles Petitot | Sep 28, 2017 | Press news

“A treatment for Alzheimer’s disease? ” Medesis Pharma announces a new therapeutic approach against Alzheimer’s disease with NP03 a lithium lipidic microemulsion formulation A preclinical study published in “Translational...

Recent Posts

  • Alzheimer’s disease
  • We develop new drugs to preserve life
  • Investors
  • Medesis Pharma & Transgene prolongent leur accord de recherche collaborative
  • NanoSIRNA

Recent Comments

    Archives

    • August 2021
    • June 2021
    • January 2021
    • November 2020
    • March 2020
    • July 2019
    • October 2017
    • September 2017
    • July 2017
    • June 2017

    Categories

    • Banner in one
    • Clinical stage products
    • In one
    • Investors
    • Non classé
    • Preclinical stage product
    • Press news
    • Research
    • Technology

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • Facebook
    • X
    • Instagram
    • RSS

    Designed by Elegant Themes | Powered by WordPress

    Manage Cookie Consent
    We use cookies to optimize our website and our service. Cookie Policy
    Functional Always active
    The storage or technical access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication on an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Marketing
    The technical storage or access that is used exclusively for statistical purposes. Technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance by your ISP, or additional third-party records, information stored or retrieved for this purpose alone generally cannot be used to identify you.
    Marketing
    Storage or technical access is required to create user profiles to send advertising, or to track the user across one or multiple websites for similar marketing purposes.
    Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
    Personalize
    {title} {title} {title}